Compare SPCB & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | PDSB |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | Israel | United States |
| Employees | N/A | 10 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 37.5M |
| IPO Year | 2004 | 2015 |
| Metric | SPCB | PDSB |
|---|---|---|
| Price | $7.91 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 37.8K | ★ 264.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.13 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.10 | $0.60 |
| 52 Week High | $13.57 | $1.90 |
| Indicator | SPCB | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 48.60 |
| Support Level | $7.75 | $0.62 |
| Resistance Level | $9.86 | $1.16 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 13.27 | 57.21 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.